|Bid||1.0700 x 800|
|Ask||1.1000 x 1300|
|Day's Range||0.9682 - 1.1500|
|52 Week Range||0.9682 - 6.9000|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.50|
Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognitionCAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study in Alzheimer’s Disease with Vascular Pathology (ADv). “The need for effective new treatments for Alzheimer’s disease is immense, and
The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Viewing insider transactions for Cyclerion Therapeutics, Inc.'s ( NASDAQ:CYCN ) over the last year, we see that...